Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05065866 · ClinicalTrials.gov registry record · Phase 1
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
A Phase 1 study of Non-Hodgkin Lymphoma and Hodgkin Lymphoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT05065866: Completed Phase 1 study of Non-Hodgkin Lymphoma and Hodgkin Lymphoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT05065866 is a Phase 1 study of Non-Hodgkin Lymphoma and Hodgkin Lymphoma that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 14 participants, below the 168-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05065866, a Phase 1 study of Non-Hodgkin Lymphoma and Hodgkin Lymphoma, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to find a safe dose and to evaluate the safety and tolerability of the drug BMS-986345, in combination with duvelisib.
Primary Outcome
Maximum Tolerated Dose (MTD) of BMS-986345 in combination with Duvelisib in patients with lymphoid malignancy. The MTD is defined as the highest dose with an observed incidence of dose limiting toxicity (DLT) in no more than one out of six patients treated at a particular dose level.
Conditions Studied
Interventions
- DRUG Duvelisib
- DRUG BMS-986345
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-11-18 |
| Est. Completion | 2024-04-24 |
| Phase | Phase 1 |
What the finished NCT05065866 record still lists
NCT05065866 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 168-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (92% lower).
The record links to 4 conditions, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Duvelisib is the first listed.
NCT05065866 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05065866 about?
NCT05065866 is a clinical study titled "Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy". The purpose of the study is to find a safe dose and to evaluate the safety and tolerability of the drug BMS-986345, in combination with duvelisib.
What is the current status of trial NCT05065866?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2021-11-18. Estimated completion is 2024-04-24.
What conditions does trial NCT05065866 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloma, Lymphocytic Leukemia.
What interventions are being tested in trial NCT05065866?
The interventions under investigation include: Duvelisib (DRUG), BMS-986345 (DRUG).
Who is sponsoring clinical trial NCT05065866?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05065866 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05065866's enrollment target sits among peer trials
14 97th of 106 higher than 8 of 106 other Non-Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy